Transforming
pharmaceutical supply chains
Transforming
pharmaceutical supply chains
Everyone deserves access to life-saving medicines
Current pharmaceutical manufacturing approaches often result in inequitable access to essential medicines. The World Health Organization estimates over two billion people worldwide lack access to basic medicines.
With synthetic biology, we can build more effective solutions to sustainably and responsibly produce medicines and drive more equitable health outcomes around the world.
Our true north
We envision a world where patient care and health equity is never jeopardized by global supply chain vulnerabilities. Our mission is to transform pharmaceutical supply chains, so that drug shortages can become a problem of the past and essential medicines are readily available to those who need them.
Our true north
We envision a world where patient care and health equity is never jeopardized by global supply chain vulnerabilities. Our mission is to transform pharmaceutical supply chains, so that drug shortages can become a problem of the past and essential medicines are readily available to those who need them.
Our story
Antheia was founded in 2015 out of the Smolke Lab at Stanford University on the premise that
yeast could be programmed to efficiently produce complex pharmaceutical ingredients.
Founders Dr. Christina
Smolke, CEO and Dr. Kristy Hawkins, CSO collaborated to push the boundaries of synthetic biology, with the
steadfast belief this technology and this company will change the world.
-
2008
Smolke and Hawkins publish in Nature Chemical Biology on the production of benzylisoquinoline alkaloids in yeast.
-
2015
Antheia incorporates and raises Seed financing round. The Smolke Lab also publishes in Science, demonstrating the complete biosynthesis of medical opiates in yeast.
-
2016
Antheia receives its first National Science Foundation grant.
-
2017
Antheia raises Series A financing and is awarded two grants from the National Institute of Health.
-
2018
Antheia receives the Phase II Small Business Innovation Research grant and a second National Science Foundation grant.
-
2020
The Smolke Lab publishes in Nature, demonstrating the biosynthesis of medicinal tropane alkaloids in yeast.
-
2021
Antheia raises Series B financing.
-
2023
Antheia brings its early products to manufacturing scale and continues to develop its pipeline of KSMs and APIs for essential medicines.
Our guiding principles
Antheia strives to be a leader in transparent and transformative essential medicine production. We are guided by a set of value-based beliefs that serve as ethical imperatives in all that we do.
Access to medicine
Safety & quality
Science and technology will advance pharmaceutical manufacturing to new heights, while ensuring the industry continues to meet the highest levels of excellence across safety, quality, and regulatory.
Sustainability
Improving planetary health requires a paradigm shift in our global supply chains. We’re leading a change in medicine production that moves away from legacy agricultural sources that have cascading environmental impacts.
Equity
Reducing barriers to essential medicines allows patients to reach their full health potential. We aim to advance health equity through access, availability, and affordability to essential medicines.
Resilience
Predictable, responsive, and sustainable supply chains are the future of manufacturing and will support the production of nature-inspired solutions to overcome current pharmaceutical challenges.
Transparency
Our guiding principles
We are guided by a set of value-based beliefs that serve as ethical imperatives in all that we do.
Access to medicine
Medicines that reduce suffering are a human right, not a privilege – including but not limited to medicines used to alleviate suffering in palliative care, neurological diseases, and cancer treatment.
Safety & quality
Science and technology will advance pharmaceutical manufacturing to new heights, while ensuring the industry continues to meet the highest levels of excellence across safety, quality, and regulatory.
Sustainability
Improving planetary health requires a paradigm shift in our global supply chains. We’re leading a change in medicine production that moves away from legacy agricultural sources that have cascading environmental impacts.
Equity
Reducing barriers to essential medicines allows patients to reach their full health potential. We aim to advance health equity through access, availability, and affordability to essential medicines.
Resilience
Predictable, responsive, and sustainable supply chains are the future of manufacturing and will support the production of nature-inspired solutions to overcome current pharmaceutical challenges.
Transparency
Our leadership team
Solving some of the toughest challenges in pharmaceutical manufacturing takes a special team. Antheia’s leadership comprises bright minds and tenacious curiosity, coalesced around a shared vision for the future. We are passionate and relentless in our mission to transform pharmaceutical supply chains.
Christina Smolke, PhD
Co-Founder & CEO
Kristy Hawkins, PhD
Co-Founder & CSO
Zack McGahey
Chief Operating Officer
Heidi Pucel
Chief People Officer
Jesse Ahrendt
Head of Quality Assurance and Regulatory Affairs
Pavel Aronov, PhD
Head of Bioanalytics
Guerin Kob
Head of Supply Chain
Ben Kotopka, PhD
Head of Data Science
Jordyn Lee
Head of Communications
Farrah Pulce, PMP
Head of Project Management
Richard Sherwin
Head of Commercialization
Suzanne Sato
Head of Downstream Processing
Ken Takeoka
Head of Biology
Yen-Hsiang Wang, PhD
Head of Strategy, Partnerships, and Finance
Yihui Zhu, PhD
Head of Fermentation
Christina Smolke, PhD
Co-Founder & CEO
Kristy Hawkins, PhD
Co-Founder & CSO
Zack McGahey
Chief Operating Officer
Christina Smolke, PhD
Co-Founder & CEO
Kristy Hawkins, PhD
Co-Founder & CSO
Zack McGahey
Chief Operating Officer
Heidi Pucel
Chief People Officer
Jesse Ahrendt
Head of Quality Assurance and Regulatory Affairs
Pavel Aronov, PhD
Head of Bioanalytics
Guerin Kob
Head of Supply Chain
Ben Kotopka, PhD
Head of Data Science
Jordyn Lee
Head of Communications
Farrah Pulce, PMP
Head of Project Management
Richard Sherwin
Head of Commercialization
Suzanne Sato
Head of Downstream Processing
Ken Takeoka
Head of Biology
Yen-Hsiang Wang, PhD
Head of Strategy, Partnerships, and Finance
Yihui Zhu, PhD
Head of Fermentation
Board of directors
John Nicols
Patrick Yang, PhD
Ram Shriram
Kristy Hawkins, PhD
Christina Smolke, PhD
Board of Directors
-
John Nicols
-
Patrick Yang, PhD
-
Ram Shriram
-
Kristy Hawkins, PhD
-
Christina Smolke, PhD
Global Javascript Test
Note to self : here I added the exact same code as the above our story timeline, to confirm if the global Javascript will have individual scrolltriggers per sider
Founders Dr. Christina
Smolke, CEO and Dr. Kristy Hawkins, CSO collaborated to push the boundaries of synthetic biology, with the
steadfast belief this technology and this company will change the world.
-
2008
Smolke and Hawkins publish in Nature Chemical Biology on the production of benzylisoquinoline alkaloids in yeast.
-
2015
Antheia incorporates and raises Seed financing round. The Smolke Lab also publishes in Science, demonstrating the complete biosynthesis of medical opiates in yeast.
-
2016
Antheia receives its first National Science Foundation grant.
-
2017
Antheia raises Series A financing and is awarded two grants from the National Institute of Health.
-
2018
Antheia receives the Phase II Small Business Innovation Research grant and a second National Science Foundation grant.
-
2020
Smolke Lab publishes in Nature, demonstrating the biosynthesis of medicinal tropane alkaloids in yeast.
-
2021
Antheia raises Series B financing.
-
2023
Antheia brings its early products to manufacturing scale and continues to develop its pipeline of KSMs and APIs for essential medicines.